T he proliferation and migration of smooth muscle cells (SMCs) are major contributors to the formation of a neointima after the vascular injury that occurs during coronary interventions. 1, 2 Medial SMCs proliferate in response to growth factors elaborated from various cells, including platelets, endothelial cells, and SMCs. 3,4 SMC proliferation is followed by a wave of migration across the internal elastic lamina into the adjacent intimal layer. 3, 4 In the intima, SMCs undergo phenotypic changes and secrete a variety of ECM (extracellular matrix) proteins, including vitronectin (VN) and osteopontin (OPN). 5, 6 Many of these ECM proteins are effective haptotactic factors that further augment SMC migration. 7, 8 The accumulation of SMC and ECM contributes to intimal lesion formation and restenosis.
SMC migration is largely dependent on the integrin family of receptors interacting with ECM components. 9 Integrins are heterodimeric transmembrane receptors that mediate cell-cell and cell-matrix interactions. 10 ECM proteins attach to integrins primarily via the RGD (arginine-glycine-aspartic acid) tripeptide sequence, which is the principal motif through which binding to integrins is mediated. 11 Of the integrin receptors, ␣ v ␤ 3 appears to be the major mediator of migration.
A variety of agents, including RGD peptides, antibodies, and selective small molecule inhibitors 12, 13 directed at ␣ v ␤ 3 , have been used to reduce SMC migration in vitro. Furthermore, several of these agents have inhibited intimal hyperplasia in normolipidemic, nonatherosclerotic animal models. [12] [13] [14] [15] [16] The increased expression of ␣ v ␤ 3 in atherosclerotic versus normal coronaries 17 demonstrates that this receptor could potentially contribute to plaque progression or restenosis. Abciximab, a humanized monoclonal Fab fragment that binds to the fibrinogen and VN receptors with equal affinity, 18 has a long-term favorable effect on the outcomes after coronary interventions. 19 This finding has led to speculation that part of the beneficial effect of abciximab could be mediated via anti-␣ v ␤ 3 effects rather than solely through anti-platelet activity. To further examine the importance of ␣ v ␤ 3 , we tested the effect of Vitaxin, a humanized form of LM609, 20 which is a function-blocking antibody to ␣ v ␤ 3 , on intimal hyperplasia in the balloon-injured hypercholesterolemic rabbit.
Materials and Methods
Vitaxin, a humanized IgG1 monoclonal antibody to ␣ v ␤ 3 derived from the parent antibody LM609, 20 was obtained from IXSYS.
Pharmacokinetic studies performed at IXSYS demonstrated a mean maximum plasma concentration of Vitaxin of 95.6 g/mL and an elimination half-life (t 1/2␤ ) of 60.3 hours after a dose of 5 mg/kg in New Zealand White (NZW) rabbits. The mean maximum plasma concentration of Vitaxin after a dose of 1 mg/kg was 16.8 g/mL, and the t 1/2␤ was 38.9 hours. NZW rabbits were obtained from Robinson Company (Winston-Salem, NC). A Cobra 4.0-mm angioplasty balloon catheter was obtained from SCIMED. Serum-free DMEM was purchased from Life Technologies. Rabbit aortic SMCs (Rb-1) were a kind gift from Dr Maurice Nachtigal, University of South Carolina School of Medicine (Columbia, SC). 21 Wild-type recombinant human VN was expressed and purified (N. Wajih, D.C. Sane, unpublished data, 1998). Human IgG1 was purchased from Sigma, and affinity-purified goat anti-human IgG/rhodamine conjugate was purchased from Jackson ImmunoResearch Laboratories. The In Situ Cell Death Detection Kit, AP was purchased from Boehringer Mannheim, and the Vectastain Elite ABC Kit was purchased from Vector Laboratories. The antibody to transforming growth factor-␤ 1 (TGF-␤ 1 ; AB-100-NA) was purchased from R&D Systems.
Balloon Injury
Balloon angioplasty was performed on the iliac arteries of 20 NZW rabbits weighing 4 kg. These rabbits were fed a high-cholesterol diet, composed of 0.5% cholesterol, 2.5% peanut oil, and 97% rabbit chow, for 1 week before balloon injury and until euthanization at 1 month. The rabbits were randomized to 3 groups, as follows: saline control (nϭ6), low-dose Vitaxin (LDV; 0.5 mg/kg; nϭ6), and high-dose Vitaxin (HDV; 5.0 mg/kg; nϭ8). Vitaxin-treated rabbits received the first dose intra-arterially immediately before balloon injury. Subsequent doses of Vitaxin were given intramuscularly daily for 2 days after balloon injury. Saline, LDV, and HDV infusions were administered in equal volumes in syringes that were coded by a collaborator not involved in the care of the rabbits. The investigators remained blinded to the treatment groups until all analyses were completed.
Before balloon injury, the rabbits were anesthetized with an intramuscular injection of ketamine hydrochloride (50 mg/kg), acepromazine maleate (0.25 mg/kg), and buprenorphine hydrochloride (0.025 mg/kg). A longitudinal incision was made in the ventral neck region, Ϸ0.5 inches to the right of the trachea. Approximately 2 inches of the common carotid artery was isolated. A 4 -0 Ti-Cron polyester tie was used to ligate the cranial end of the carotid and to anchor the caudal end. Arterial puncture was performed with a 20-gauge radial artery catheter through which a 0.014-inch floppy guide wire was introduced. The guide wire, with a "J" tip, was advanced into the abdominal aorta with fluoroscopic guidance. The radial catheter was removed, and a 4.0-mm Cobra angioplasty balloon catheter, preinfused with heparinized saline, was inserted over the guide wire and advanced to the middle of the right iliac artery. The guide wire was removed from the catheter, and drug treatment was administered through the catheter into the iliac artery. Arterial injury was performed by inflating the balloon 3 times for 30 seconds at 5 atm of pressure. The balloon was then removed from the animal, and the caudal end of the exposed external carotid was ligated. The skin incision was closed using a 2.0 black monofilament nylon suture. A 2-g (IM) injection of cefazolin was given as a prophylaxis for infection. All procedures on animals were performed under a protocol approved by the Animal Care and Use Committee at Wake Forest University School of Medicine (protocol A95-069).
Cholesterol Measurements
Blood was collected at time of injury and at time of euthanization and centrifuged at 1400g for 10 minutes, and the serum was frozen at Ϫ20°C until it was assayed within 2 months after collection. Total cholesterol levels were measured by the Lipid Analytic Laboratory at the Wake Forest University School of Medicine using an assay based on the cholesterol esterase/cholesterol oxidase colorimetric procedure. 22 Total cholesterol values are expressed as mg/dL (meanϮSEM).
Harvesting Iliac Arteries
The iliac arteries were harvested 1 month after balloon injury. Rabbits were anesthetized with ketamine hydrochloride (100 mg/kg) and acepromazine maleate (0.50 mg/kg). A longitudinal abdominal incision was made to expose the aorta, inferior vena cava, and iliac arteries. A 22-gauge catheter (Angiocath) was inserted into the abdominal aorta, and blood was collected for cholesterol measurements. An 18-gauge catheter was then inserted in the inferior vena cava to allow for adequate drainage of the perfused paraformaldehyde (PFA). The abdominal aorta was then perfused with saline for 15 minutes at 80 mm Hg. The rabbits were then euthanized with an injection of pentobarbital sodium (Beuthanasia-D special) (390 mg/kg) into the heart. The aortas were perfused with 4% PFA (in PBS, at 4°C) at 80 mm Hg for 15 minutes. After perfusion, the right and left iliac arteries and aorta were dissected free and placed in 4% PFA for 24 to 48 hours.
Tissue Processing
The right iliac artery was extracted from the rabbit and then cut into 1-inch sections and placed into specimen jars filled with 4% PFA at 4°C. These sections were then cut into 4.0-mm sections and processed (using a Sakura VIP 3000 tissue processor) with a dehydration series of ethanol followed by xylene and then embedded in paraffin. The paraffin-embedded arteries were cut into 5-m sections with a Leica 2025 microtome and placed in a warm gelatin water bath. Sections were then placed on slides, dried in a 70°C to 80°C oven for 30 minutes, and stained with Gill's hematoxylin and eosin on an automatic slide stainer (Leica Autostainer XL).
Morphometric Analysis
Four arterial sections per rabbit were viewed using an Olympus CK2 microscope and imported into Image Pro Plus (Media Cybernetics) to perform computer-assisted digital planimetry. Briefly, areas of interest were drawn around the lumen, media, and neointima. The total intimal area (area within the internal elastic lamina minus the lumen) and the medial area [area within the external elastic lamina (EEL) minus the internal elastic lamina (IEL)] were determined. Measurements were expressed as mm 2 ϮSEM.
Cell Migration Assay
The cell migration assay was performed as previously described. 23 Briefly, modified Boyden chambers with a 6.5-mm diameter, 10-m thickness, and 8.0-m porous membrane separating the upper and lower chambers were used. The lower surface of the membrane was coated with VN (10 g/mL) for 16 hours in PBS (pH 7.4) at 4°C. Excessive ligand was removed, and the lower chamber was filled with 0.3 mL of serum-free DMEM/0.5% BSA. The chamber was equilibrated for 2 hours at 37°C in a 5% CO 2 incubator before the migration assay. Rb-1 cells were harvested, and 50 000 cells were added to each well. Vitaxin was added to the upper chamber of the wells at varying concentrations (0 to 200 g/mL). Migration was allowed to proceed for 8 hours at 37°C in a 5% CO 2 incubator. At the end of the migration assay, the upper surface of the membrane was wiped with a cotton-tipped applicator to remove nonmigratory cells, and the cells that migrated to the undersurface were fixed in 10% neutral buffered formalin and then stained with Diff-Quick. The number of stained cells per high-powered field (HPF; ϫ200) were counted, and the average of 3 nonoverlapping fields was determined. Random movement was evaluated using PBS-coated membranes. Each determination represents the average of 3 individual wells, and error bars indicate ϮSEM.
To control for nonspecific antibody effects, human IgG1 was added at varying concentrations (200, 150, 100, and 0 g/mL), and migration assays were performed as described above.
Immunofluorescence Binding Studies
The binding of Vitaxin to Rb-1 cells was analyzed using immunofluorescence. Cells were cultured in 35-mm cell dishes and then rinsed with Dulbecco's PBS (D-PBS) at 4°C followed by PBS containing 10 mg/mL BSA. Vitaxin (10 g/mL) or the nonimmune human IgG1 (10 g/mL) was added to subconfluent cells and incubated at 4°C for 1 hour. Cells were then rinsed 5 times in D-PBS at 4°C, followed by an incubation with the secondary antibody, affinity-purified goat anti-human IgG/rhodamine conjugate (25 g/mL in BSA/D-PBS), for 30 minutes at 4°C. Cells were rinsed 5 times with PBS at 4°C, fixed with 3.7% formaldehyde in PBS at room temperature for 10 minutes, and then rinsed with PBS and mounted under a No. 1, 25-mm circular coverslip in 90% glycerol/ 10% PBS. Cells were viewed using a Zeiss Axioplan fluorescence microscope equipped with a 40ϫ, numerical aperture 1.3 PlanNeofluar objective, rhodamine filters, and phase-contrast optics. Images were captured using a SPOT digital charge-coupled device camera and printed using a Kodak 8650 dye sublimation printer.
Immunohistochemistry
Immunohistochemical detection of TGF-␤ 1 was performed on paraffin-embedded iliac artery sections. Briefly, slides were deparaffinized and hydrated through a series of xylenes and graded alcohol series. Slides were then rinsed in water, incubated in 0.3% H 2 O 2 for 30 minutes, and blocked with 0.1% BSA for 30 minutes. The primary antibody for TGF-␤ 1 was placed on slides for 30 minutes, at which point slides were rinsed with PBS and then incubated with diluted biotinylated secondary antibody for 30 minutes. After further washes in PBS, staining was achieved using the ABC Vectastain Elite peroxidase system kit (Vector Laboratories). 3,3Ј-Diaminobenzidine was used to visualize the staining. Slides were then counterstained with hematoxylin.
Apoptosis Detection
Paraffin-embedded iliac arteries were deparaffinized and prepared for staining as mentioned above. Apoptotic nuclei were detected using the In Situ Cell Death Detection Kit (Boehringer Mannheim), essentially a TUNEL assay that detects 3Ј-OH groups of fragmented DNA. Briefly, slides were treated with proteinase K for 30 minutes at 37°C. Sections were then rinsed with PBS, and 50 L of the TUNEL reaction mix was placed on the slides for 1 hour at 37°C.
Slides were rinsed with PBS and incubated with 50 L of the converter-alkaline phosphatase mixture for 30 minutes at 37°C. Sections were then rinsed with PBS, and incubated with the nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) color detection solution containing 0.17 mg/mL BCIP and 0.33 mg/mL NBT [in mmol/L, Tris-HCL (pH 9.5) 100, NaCl 100, and MgCl 2 5] . Finally, slides were rinsed with PBS.
Apoptotic nuclei were quantified by counting the number of stained nuclei per HPF. Three sections were used from each experimental group, and apoptotic nuclei were counted in 5 separate HPFs per artery section (a total of 15 HPFs were averaged).
Statistical Analysis
All results are expressed as meanϮSEM. Statistical significance between mean differences was determined using a 2-tailed Student t test. A P value Ͻ0.05 denoted statistical significance.
Results

Total Cholesterol Levels
Cholesterol levels in rabbits fed a normal diet were 25.2Ϯ2.4, 403.5Ϯ100.0 after being fed a high-cholesterol diet for 1 week (at time of injury), and 563.3Ϯ325.2 mg/dL at the time of euthanization.
Systemic Administration of Vitaxin Significantly Reduces Neointima Formation and Intima-Media Ratio (IMR) After Balloon Injury
Vitaxin significantly reduced neointima formation after balloon injury in both the LDV and the HDV groups as compared with saline control (Figure 1) . The difference between saline and Vitaxin treatment was statistically significant (PϽ0.0005 for saline versus HDV and for saline versus LDV), but the difference in the 2 dosing regimens was not statistically significant (Figure 2) . The neointima area was 1.08Ϯ0.13 mm 2 in the saline group, 0.30Ϯ0.05 mm 2 in the LDV group, and 0.31Ϯ0.15 mm 2 in the HDV group. Likewise, the IMR was significantly less in the Vitaxintreated groups than in the saline control group (Figure 3) . The IMR for the LDV group was 0.46Ϯ0.05, representing a significant reduction from the saline control group, which had an IMR of 1.72Ϯ0.16 (PϽ0.0005). The IMR in the HDV group was 0.49Ϯ0.07, which also represented a significant reduction from the saline control (PϽ0.0005). There was not a significant difference between the LDV and HDV groups.
Effect of Vitaxin on Arterial and Lumen Size
The Vitaxin-treated rabbits had a smaller total artery size (the area encompassed by the EEL; Figure 4 ). The total area in the saline group was 2.6Ϯ0.2 mm 2 . Systemic administration of Vitaxin was associated with a significant decrease in artery size in both LDV and HDV groups. The artery size in the LDV group is 1.94Ϯ0.17 mm 2 and 1.42Ϯ0.1 mm 2 in the HDV group; Pϭ0.01 (saline versus LDV) and PϽ0.0005 (saline versus HDV).
There was no significant difference in lumen size between the saline and LDV groups; however, the HDV had a lumen size of 0.56Ϯ0.04 mm 2 , which was significantly smaller than the lumen size in the saline group (lumen area of 0.95Ϯ0.08 mm 2 ; PϽ0.0005, Figure 5 ).
Effect of Vitaxin on Rb-1 Cell Migration
Vitaxin dose-dependently inhibited Rb-1 SMC migration ( Figure 6 ). This reduction was significant at a concentration of 20 g/mL. The IC 50 of Vitaxin was Ϸ70 g/mL. The maximum inhibition of migration was achieved at a concentration of 150 g/mL, with a 60% decrease in migration as compared with control (PϽ0.0001). As seen in the inset, IgG controls had no effect on cellular migration.
Immunofluorescence Binding Studies
Human IgG1 was used to control for nonspecific antibody binding ( Figure 7A and 7AЈ). As seen in Figure 7AЈ , no fluorescent label was apparent in cells treated with the nonimmune IgG control. Rb-1 cells treated with Vitaxin (10 g/mL, Figure 7BЈ ) showed intense labeling on the cellular surface.
Effect of Vitaxin on TGF-␤ 1 Accumulation
Both LDV-and HDV-treated groups had significantly lower amounts of TGF-␤ 1 accumulation within the artery wall as compared with saline control (Figure 8 ).
Effect of Vitaxin on Levels of Apoptosis
Both LDV-and HDV-treated groups had significantly higher levels of apoptotic nuclei within the intima and media of the artery as compared with saline control (Figures 9 and 10 ). The number of apoptotic nuclei in the LDV group was 139Ϯ9.46/HPF and 129.67Ϯ11.64/HPF in the HDV group, compared with the saline control-treated group, which had 41.2Ϯ3.54 apoptotic nuclei/HPF (PϽ0.0005). There was no significant difference in apoptotic levels between the Vitaxintreated groups.
Discussion
Recent attention has focused on a number of processes that contribute to lesion formation after arterial injury, including SMC migration, 1-4 apoptosis, 24 ECM production, 25 and angiogenesis. 26, 27 The integrin receptor, ␣ v ␤ 3 , contributes to all of these events and is therefore a potential target for therapies aimed at inhibiting lesion formation after arterial injury. There are many reports of decreased lesion formation in response to inhibition of ECM protein-integrin interactions. [12] [13] [14] [15] [16] Emerging data using selective inhibitors support the importance of ␣ v ␤ 3 as a major contributor to lesion formation. Van der Zee et al 16 showed that LM609, an anti-␣ v ␤ 3 -specific antibody and the precursor of Vitaxin, reduced neointimal hyperplasia after injury to the iliac artery of male NZW rabbits. Furthermore, recent data from Srivatsa et al 13 demonstrated that a 28-day infusion of the selective ␣ v ␤ 3 peptidomimetic antagonist XJ735 resulted in a marked reduction in neointimal area and lumen stenosis in a porcine model of balloon injury.
In the present study, we report that systemic administration of Vitaxin, a monoclonal antibody to the VN receptor ␣ v ␤ 3 inhibits neointimal formation after balloon injury. Equally significant inhibition was seen with both low-dose (0.50 mg/kg) and high-dose (5.0 mg/kg) administration of Vitaxin. Vitaxin administration resulted in a 72% reduction in neointima area in the LDV group and a 71% reduction in neointima size in the HDV group as compared with saline control. The IMR in the LDV group was 73% less than in the saline control group and was 72% less in the HDV. Vitaxin was administered to each rabbit with an initial intra-arterial dose on the day of injury and subsequent intramuscular injections on days 2 and 3 after injury. Short-term administration (single daily doses for 3 days) of the antibody was sufficient to sustain the reduction in neointimal hyperplasia until vessel harvest at 1 month after balloon injury. Prior studies have used continuous intravenous infusions of 3 to 28 days of the ␣ v ␤ 3 antagonist. Our study was also the first to examine the effect of ␣ v ␤ 3 blockade in hypercholesterolemic animals. Both Van der Zee 16 and Srivatsa et al 13 studied ␣ v ␤ 3 blockade in normolipidemic models. In the present study, rabbits were fed a high-cholesterol diet for 1 week before balloon injury and after injury until euthanization. Vitaxin was successful in reducing neointimal hyperplasia even in the presence of hypercholesterolemia, which is a stimulus to ␣ v ␤ 3 expression. 28 There are many potential mechanisms by which Vitaxin could reduce neointima formation after balloon injury. These include inhibition of SMC migration, inhibition of TGF-␤ 1 production, potentiation of apoptosis, inhibition of angiogenesis, and modulation of the activation or the localization of matrix metalloproteinase (MMP)-2.
SMC migration from the media into the intima of an injured artery is a fundamental step in the response to injury, and ␣ v ␤ 3 is a major mediator of this process. [12] [13] [14] [15] [16] Choi et al 12 demonstrated that ␣ v ␤ 3 was evenly distributed on the surface of nonmigrating SMCs but redistributed to the leading edge after platelet-derived growth factor-AB-induced migration. This migration was blocked with a monoclonal antibody to ␣ v ␤ 3 (LM609) and with an RGD-containing peptide (Gpen-GRGDSPCA). 12 Brown et al 7 also demonstrated that the same RGD-containing peptide, as well as a polyclonal antibody to ␣ v ␤ 3 , inhibited SMC migration. Yue et al 29 demonstrated that OPN is a haptotactic factor for rat SMC and that an antibody to the rat ␤ 3 integrin, but not the ␤ 1 integrin, inhibited OPN-induced migration. This group suggested that ␣ v ␤ 3 is the major integrin involved in OPN-induced SMC migration. Clyman et al 30 demonstrated that the migration of lamb ductus arteriosus SMCs over a variety of ECM substrates, including fibronectin, laminin, type I collagen, type IV collagen, and VN, was ␣ v ␤ 3 dependent.
We confirmed that Vitaxin inhibits rabbit SMC (Rb-1) migration (Figure 6 ). At a concentration of 150 g/mL, we found a 60% decrease in migration from baseline. However, at the maximum achievable concentration in the LDV group (Ϸ10 g/mL), there would be minimal inhibition of migration (Figure 6 ), despite intense cell binding (Figure 7) . In contrast, the maximum Vitaxin concentration in the HDV group (Ϸ96 g/mL) would produce Ϸ50% inhibition of migration ( Figure 6 ). Since Vitaxin did not cause total inhibition of SMC migration in this assay, and since LDV and HDV decreased neointima formation by nearly equal amounts despite different achievable plasma concentrations, there may be other mechanisms for the Vitaxin-mediated inhibition of neointimal hyperplasia. One possibility is that Vitaxin reduced the rate of re-endothelialization after injury. The extent of endothelial injury and the rate of recovery may be important determinants of vascular healing after arterial injury. 31 This mechanism is unlikely, however, since equal luminal endothelial coverage was seen in all groups at 4 weeks (data not shown) and since Van der Zee et al 32 found no reduction of endothelial regrowth by LM609 at 2 and 4 weeks after balloon injury.
We have also shown that in both Vitaxin treatment groups, TGF-␤ 1 accumulation was less than in the saline-treated group (Figure 8 ). Ribeiro et al 33 have demonstrated that the denatured, heparin-binding form of VN, binding to ␣ v ␤ 3 , induces TGF-␤ 1 expression in cultured bovine aortic endothelial cells. This induction was dependent on the VN-␣ v ␤ 3 Figure 6 . Effect of Vitaxin on Rb-1 SMC migration. Cell migration assays were performed using Transwell chambers with VN coated on the lower membrane surface. Cells and varying concentrations of Vitaxin were added to the upper chamber. Vitaxin dose-dependently inhibited Rb-1 cell migration. At 150 g/mL of Vitaxin, SMC migration was inhibited by 60% (PϽ0.0001). As seen in the inset, IgG control at the higher concentrations had no effect on cellular migration.
interaction, since both RGD peptides and a monoclonal antibody to ␣ v ␤ 3 (LM609) were able to block the induction of TGF-␤ 1 . TGF-␤ 1 , which is upregulated in restenosis, 34 induces the expression of various ECM proteins known to stimulate SMC migration and, at the same time, upregulate the expression of inhibitors of matrix degradation, including plasminogen activator inhibitor-1 and tissue inhibitors of metalloproteinases. 35 Given that balloon injury and hypercho- Figure 7 . Immunofluorescence binding studies. The binding of Vitaxin at a concentration achievable in the low-dose treatment group was studied using immunofluorescence. Rb-1 cells were incubated with Vitaxin (10 g/mL) or nonimmune human IgG1 (10 g/mL). A and AЈ, Rb-1 cell that has been treated with nonimmune IgG control; B and BЈ, Rb-1 cell treated with Vitaxin (panels A and B are phase contrast images, and panels AЈ and BЈ are immunofluorescence images). As seen in panel AЈ, the control antibody does not bind to the cellular surface. In contrast, cells incubated with Vitaxin demonstrate intense punctate fluorescence that is maximal at the cell periphery (panel BЈ). lesterolemia have been shown to induce TGF-␤ 1 expression, 34, 36, 37 the inhibition of TGF-␤ 1 production by Vitaxin could be an important mechanism for its effects in this setting.
The integrin receptor ␣ v ␤ 3 also regulates cellular apoptosis, or programmed cell death. Using the TUNEL technique, Isner et al 38 reported high levels of apoptotic cells in human atherosclerotic lesions and even higher levels in restenotic lesions. Inhibiting the ␣ v ␤ 3 receptor could therefore result in an increase in apoptosis, reducing cell number and, therefore, reducing neointimal area. This induction of apoptosis after inhibition of ␣ v ␤ 3 has also been shown in the microvasculature within tumors. 39 We have shown that levels of apoptosis were significantly higher in both Vitaxin-treated groups as compared with saline control (Figures 9 and 10 ). Vitaxinmediated enhancement of apoptosis in the injured artery could result in a decrease in plaque formation.
Finally, ␣ v ␤ 3 may be involved in reducing neointimal hyperplasia after arterial injury by regulating the activation and localization of MMPs and by inhibiting angiogenesis. It has been shown that MMP-2 binds directly to ␣ v ␤ 3 on angiogenic blood vessels and on melanoma tumor cells. 40 Because of the proteolytic activities of MMP-2, cellular migration through the surrounding ECM of the media and intima is stimulated. 41, 42 Blockade of ␣ v ␤ 3 by Vitaxin could prevent the localization and activation of MMP-2 on the ␣ v ␤ 3 receptor, therefore decreasing cellular migration. Because ␣ v ␤ 3 also mediates angiogenesis 27 and because plaque neovascularization may provide a nutrient blood supply, perhaps sustaining plaque growth, inhibition of ␣ v ␤ 3 could reduce intimal growth by starving the plaque.
Although intimal hyperplasia contributes to restenosis after arterial injury, it is not the sole determinant of this process. The narrowing of the entire vessel wall after injury may also contribute to the narrowing of the lumen. 43 Indeed, our study makes a strong case for the importance of vascular remodeling after arterial injury. Although it is possible that the control group had more extensive remodeling to compensate for the increased intimal hyperplasia (the Glagov phenomenon 44 ), a more likely interpretation of our data is that Vitaxin caused a dose-dependent enhancement of vessel constriction that offset its inhibitory effect on intimal hyperplasia.
The contraction of the vessel wall after injury has been compared with wound contracture, a process that involves cell-matrix interactions mediated by integrin receptors. 45 The VN receptor has a defined role in mediating contraction of extracellular matrices. 46, 47 Given its role in ECM contraction, an antibody to ␣ v ␤ 3 might be predicted to produce favorable remodeling or an increase in the total vessel area. Our finding that vessel cross-sectional area decreased suggests that other factors affecting the dimensions of the vessel wall must be considered.
Vitaxin could enhance vessel constriction through several mechanisms. By binding to ␣ v ␤ 3 , Vitaxin could prevent the vasodilatory responses that are mediated by the VN receptor. 48 -50 Furthermore, antibodies to ␣ v ␤ 3 could potentially block the conversion of pro-MMP-2 to active MMP-2, an event that has been reported to occur on melanoma cell VN receptors. 39 Collagen fragments that are generated by MMP activity induce vasodilation that is mediated via ␣ v ␤ 3 . 48, 51, 52 Thus, an antibody to ␣ v ␤ 3 could prevent both the generation of dilatory collagen fragments as well as their subsequent binding to ␣ v ␤ 3 .
Our results are distinct from those of some other studies that have examined ␣ v ␤ 3 inhibitors. Srivatsa et al 13 studied expression of ␣ v ␤ 3 after balloon injury to coronary arteries of normolipidemic pigs as opposed to the setting of hypercholesterolemia. Also, there was no significant effect of XJ735 on the arterial size, as measured by the EEL area. 13 A recent study of abciximab administration to atherosclerotic cynomolgus monkeys showed a significant decrease in arterial Figure 9 . Effect of Vitaxin on vascular apoptosis. An in situ apoptosis assay was performed on representative sections from each experimental group as described in Materials and Methods. Both LDV-and HDV-treated arteries had a significant increase in the number of total apoptotic nuclei (stained dark) within the intima and media of the artery. Arrows indicate IEL, and L, lumen. wall area in the c7E3-treated animals, a finding that is similar to our report. 53 Differential effects of inhibitory antibodies and small molecule inhibitors of ␣ v ␤ 3 could be elicited by the known differences in signal transduction of receptors depending on whether the receptor is occupied by a simple ligand or both occupied and aggregated by inhibitory antibodies. 54 In summary, we have found that Vitaxin, a functionblocking antibody to the ␣ v ␤ 3 receptor, resulted in a marked reduction of neointimal area after balloon injury. We have shown that possible mechanisms of the effect of Vitaxin on decreasing neointimal hyperplasia could include a decrease in TGF-␤ 1 accumulation and an increase in cellular apoptosis. Previous studies have shown a reduction in neointimal area after arterial injury in the presence of integrin antagonists, but most of these inhibitors were not selective for ␣ v ␤ 3 . Our data are also novel in that a short, 3-day administration of Vitaxin was effective in reducing lesion size after angioplasty, unlike the continuous 1-month infusion of drug treatment as seen with XJ735. A short infusion of the drug is a more practical clinical situation. A third important finding is that Vitaxin was effective even in the presence of hypercholesterolemia, a condition we have shown markedly accentuates ␣ v ␤ 3 accumulation. Hypercholesterolemia is a known risk factor for coronary artery disease and is therefore a clinically relevant setting in which to study the efficacy of ␣ v ␤ 3 blockade.
Unexpectedly, Vitaxin therapy was also associated with constriction of the artery. It is possible that a dose of Vitaxin of Ͻ0.5 mg/kg would have retained potency at inhibiting intimal hyperplasia, but with a more favorable effect on remodeling. Further studies need to be performed to fully understand the potential vasoconstrictory effects of Vitaxin. However, given that vascular recoil and negative remodeling are prevented by stent implantation, 55 which is an increasingly popular method of vascular intervention, antibodymediated ␣ v ␤ 3 inhibition with Vitaxin (perhaps using lower doses) could be considered in this setting.
